Company Overview and News

0
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-06-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-06-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-06-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment (ZEEEY) Presents At Nomura Investment Forum Asia 2018 - Slideshow

2018-06-04 seekingalpha
The following slide deck was published by Zee Entertainment Enterprises Ltd. ADR in conjunction with this event.
ZEEEY 505537 ZEEL

0
Most FMCG firms beat Street math in Q4

2018-05-16 thehindubusinessline
Priya Kansara The consumer sector is among the few in the economy on which analysts and investors have pinned high hopes for a strong financial performance in the March quarter. And not without reason, given the low base of the post-demonetisation period and better macro environment compared to other industries.
500820 KAJARIACER DABUR NESTLEIND HINDUNILVR 533155 ASIANPAINT DBRQY JUBLFOOD 532424 GDRJY 500096 ZEEEY JBLWY 505537 500233 500696 GODREJCP ZEEL 500790 NSZTY

0
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

26
Sony's Subsidiary to Acquire a Stake in Peanuts Holdings

2018-05-15 zacks
Sony Corporation’s (SNE - Free Report) wholly-owned subsidiary, Sony Music Entertainment, recently entered into a definitive agreement with DHX Media Ltd. Per the deal, Sony Music will acquire 49% of the 80% equity interest held by DHX Media in Peanuts Holdings LLC. Notably, this $185-million agreement is expected to conclude on or about Jun 30, 2018.
DHX.A CABO PVH DHXM ZEEEY 505537 DMQHF SNE TSG SNEJF ZEEL

0
Zee Entertainment Enterprises Limited - Reply to Clarification Sought

2018-05-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

6
Sun TV hits 8-month high on Q4 results

2018-05-14 thehindubusinessline
SunTV has reported a 23 per cent growth in March-quarter profit, with advertisement revenue growing 26 per cent, and subscription revenue rising 28 per cent.
ZEEEY RAJTV 505537 532826 SNQVY 500570 ZEEL TATAMOTORS 532733 SUNTV TTM

0
Zee Entertainment Enterprises Limited - Clarification

2018-05-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

12
Zee Entertainment up 1% despite 85% fall in Q4 profit; CLSA maintains buy

2018-05-11 moneycontrol
Shares of Zee Entertainment Enterprises rose 1.5 percent intraday Friday despite weak set of numbers for the quarter ended March 2018.
MS.PRI ZEEEY MS.PRK MS.PRE 505537 MS.PRF MS.PRG MS MS.PRA ZEEL

0
Zee Entertainment Q4 profit declines 84.8% to Rs231 crore

2018-05-10 livemint
New Delhi: Zee Entertainment Enterprises Ltd (ZEEL), which operates channels such as Zee TV and Zee Cinema, reported an 84.8% decline in net profit for the March quarter, despite a 12.9% growth in operating revenue.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Financial Result Updates

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Outcome of Board Meeting

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...